Lisata Therapeutics Q3 net loss narrows to $4.2 mln

Lisata Therapeutics

06/11/2025 22:17

Overview

Lisata Q3 net loss narrows to $4.2 mln from $4.9 mln yr/yr

Operating expenses decreased by 17.3% to $4.4 mln in Q3 2025

Cash runway extended into Q1 2027

Outlook

Company projects cash reserves will fund operations into Q1 2027

Result Drivers

CASH RUNWAY EXTENSION - Cash reserves expected to fund operations into Q1 2027, with no debt

Key Details

Metric
Beat/Miss
Actual
Consensus Estimate
Q3 EPS
-$0.49
Q3 Net Income
-$4.25 mln
Q3 Operating Expenses
$4.41 mln
Q3 Operating Income
-$4.41 mln


Analyst Coverage

The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 3 "strong buy" or "buy", no "hold" and no "sell" or "strong sell"

The average consensus recommendation for the biotechnology & medical research peer group is "buy"

Wall Street's median 12-month price target for Lisata Therapeutics Inc is $15.00, about 84.4% above its November 5 closing price of $2.34

Press Release: ID:nGNX9H1hth

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)